Vivos Therapeutics Launches $3.6 Million Annual Cost Reduction Plan

Key Facts

1Vivos management is executing a plan to immediately reduce overhead costs by an estimated $3.6 million annually.

Vivos Therapeutics management is executing a plan to immediately reduce overhead costs by an estimated $3.6 million annually. GlobeNewswire reported that this strategic initiative focuses on streamlining operations and reducing material costs to enhance profitability while simultaneously driving top-line revenue growth. The company aims to strengthen its financial position through these immediate cost-cutting measures.

VVOS closed at $0.1341 on September 28, 2026, prior to the announcement of the restructuring plan. The stock traded within a range of $0.13 to $0.14 during its last full session as the company pivots toward its new efficiency-focused corporate strategy.